Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus is “Moderate Buy”: Of six analysts covering Aurinia Pharmaceuticals, three recommend holding, two recommend buying, and one gives a strong-buy rating. The average 12-month price target is $17.67, versus a recent opening price of $16.29.
• Quarterly earnings beat expectations: Aurinia reported earnings of $0.28 per share, ahead of the $0.24 consensus estimate, though revenue of $58.57 million fell short of the expected $80.45 million.
• Institutional ownership stands at 36.83%: Several investment firms recently initiated positions in the company, while Aurinia’s stock trades near its 50-day and 200-day moving averages and has ranged from $10.34 to $19.25 over the past year.

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP have earned an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $17.6667.

A number of research analysts have recently commented on AUPH shares. Royal Bank Of Canada boosted their target price on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a "sector perform" rating in a research report on Friday, August 7th. Wall Street Zen lowered shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 8th. Weiss Ratings raised shares of Aurinia Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 26th. Zacks Research lowered shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 21st. Finally, Bloom Burton upgraded shares of Aurinia Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 20th.

Aurinia Pharmaceuticals Price Performance

AUPH stock opened at $16.29 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.97 and a current ratio of 5.42. Aurinia Pharmaceuticals has a 1 year low of $10.34 and a 1 year high of $19.25. The firm has a market cap of $2.17 billion, a P/E ratio of 7.11 and a beta of 1.40. The stock has a 50-day simple moving average of $15.87 and a 200-day simple moving average of $15.53.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.04. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%.The firm had revenue of $58.57 million during the quarter, compared to analysts' expectations of $80.45 million. On average, equities analysts predict that Aurinia Pharmaceuticals will post 0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of AUPH. BOK Financial Private Wealth Inc. acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at approximately $32,000. Nykredit A S acquired a new stake in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at about $35,000. Global Retirement Partners LLC bought a new position in shares of Aurinia Pharmaceuticals during the second quarter worth about $41,000. Quantbot Technologies LP bought a new position in shares of Aurinia Pharmaceuticals during the second quarter worth about $45,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in Aurinia Pharmaceuticals in the third quarter worth about $48,000. Institutional investors and hedge funds own 36.83% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company's lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source